Published in AIDS Weekly, July 28th, 1997
The cytokine may thus have a therapeutic role in combination with IL-2, intermittent doses of which increase CD4+ T-cell counts in people with HIV infection.
"We hypothesize that IL-16 may be a useful adjunct to IL-2 for immune reconstitution therapy of HIV-1 infected individuals, increasing the number of CD4+ T cells while at the same time suppressing viral replication," suggested Nereida A. Parada and colleagues of the Boston University School of Medicine, Boston, Massachusetts.
Parada reported data from a study of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (1997-07-28)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.